Literature DB >> 2117828

Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus.

S Chakrabarti1, T Mizukami, G Franchini, B Moss.   

Abstract

The full-length envelope gene from an infectious human immunodeficiency virus type 2 (HIV-2) molecular clone was expressed in CD4+ and CD4- cells by a recombinant vaccinia virus vector. Pulse-chase experiments indicated that gp160 was processed into gp120 and gp41 subunits. Although large amounts of gp120 were shed into the medium, the recombinant vaccinia virus-infected cells fused with uninfected CD4+ cells. The receptor binding of HIV-2 gp120 was further analyzed using a panel composed of nine soluble CD4 mutants containing insertions of 2 amino acids within the first and second immunoglobulin-like domains. Of three mutations previously shown to interfere with HIV-1 gp120 binding, two also interfered with binding of the HIV-2 glycoprotein indicating use of the same binding site. Chemical crosslinking, sucrose gradient sedimentation, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis were employed to study the oligomerization of the envelope protein. The data indicated that gp160 assembles posttranslationally into dimers and higher oligomers that are probably tetramers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117828     DOI: 10.1016/0042-6822(90)90386-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Oligomer formation of the gB glycoprotein of herpes simplex virus type 1.

Authors:  S L Highlander; W F Goins; S Person; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains.

Authors:  Z Lu; J F Berson; Y Chen; J D Turner; T Zhang; M Sharron; M H Jenks; Z Wang; J Kim; J Rucker; J A Hoxie; S C Peiper; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences.

Authors:  R J Center; B E Kemp; P Poumbourios
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses.

Authors:  J Rucker; A L Edinger; M Sharron; M Samson; B Lee; J F Berson; Y Yi; B Margulies; R G Collman; B J Doranz; M Parmentier; R W Doms
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Authors:  P Poumbourios; W el Ahmar; D A McPhee; B E Kemp
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.

Authors:  Q J Sattentau; J P Moore; F Vignaux; F Traincard; P Poignard
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.

Authors:  E Fenouillet; I Jones; B Powell; D Schmitt; M P Kieny; J C Gluckman
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

9.  Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant.

Authors:  K R Steffy; F Wong-Staal
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion.

Authors:  Satinder S Rawat; Stephen A Gallo; Julie Eaton; Thomas D Martin; Sherimay Ablan; Vineet N KewalRamani; Ji Ming Wang; Robert Blumenthal; Anu Puri
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.